-
Demonstrations backing France's protesting students gather strength
-
Iraola backs Barcola, Wirtz to come good for Liverpool
-
Trump says US Senate as hard to defend as House in midterms
-
In a first, AI helps UK lawmaker find her voice in parliament
-
Suspected Russian drones hit two ships off Bulgaria, 11 missing
-
Pope Leo in Rome hospital for lung operation
-
Tech stocks slide on AI jitters
-
EU watchdog says smart glasses must give 'clear warnings' when recording
-
Trump asks Greece ambassador to resign amid ethics scandal
-
Houthis say Saudi Arabia strikes oil site in Yemen's capital
-
New White House spokeswoman heavy on Trump praise, light on questions in debut
-
France roiled by marches in support of protesting students
-
Emery urges Villa to make most of reduced home comfort
-
Goldman Sachs profits jump as CEO says no plans to exit
-
Flavio Bolsonaro visits father under house arrest ahead of Brazil runoff
-
Apple unveils HomeView smart display in renewed home push
-
France, Eq. Guinea in standoff over luxury Paris mansion
-
Novelist Thelyson Orelien denies AI use, admits plagiarism 'mistakes'
-
'Holding our ground': Israel demolishes dozens of Bedouin homes
-
Trump asks Greece ambassador to resign amid bribery scandal: White House
-
Hazlewood takes six as Australia beat South Africa in 1st Test
-
11 missing after ships struck off Bulgaria in latest Black Sea attack
-
Saudi coalition tells Sanaa residents to flee site before operation
-
France budget debate faces rocky start as Socialists vow to fight
-
Zverev defies 'physical issues' to reach Shanghai Masters quarter-finals
-
AI could 'change the stakes' on bioweapons: UK spy chief
-
'We're not giving up': Activist Thunberg joins France student protests
-
Sweden centre-left leader fails to form government
-
Man City captain Dias defends celebrations after Liverpool win
-
EU economy chief doubtful Russian diesel exports will affect prices
-
B2PRIME Expands Tier-1 Access and Liquidity Architecture for Sophisticated Institutional Flow
-
Capital International Highlights Multilingual Access to Its Platform as European Economic Conditions Diverge
-
STARTRADER Adds 48 US Stock CFDs with 24-Hour Weekday Trading
-
Hazlewood takes six as Australia win first Test
-
'Ink' director Danny Boyle slams Trump's Truth Social 'lies'
-
Pope Leo admitted to hospital for lung operation
-
Coach Kovac extends contract at Dortmund until 2029
-
Hungary cuts anti-LGBTQ measures from Orban-era law
-
Activist Thunberg joins France student rally after violence at protests
-
Tech stocks slump on AI jitters; oil falls
-
Archer and Bethell in England squad for Australia ODI series
-
ePlanet Brokers Publishes H1 2026 Transparency Report and Highlights Best Broker 2026 Award
-
Formula One to return to Africa in 'early 2030s' in Rwanda
-
Van Gogh work unseen in public for 60 years on show in Hong Kong
-
US actor Selma Blair charged with assault after alleged flight altercation
-
Prosecutors drop most impeachment charges against Philippine VP Duterte
-
Hungary cuts anti-LGBTQ legislation from Orban-era law
-
Hypersonic weapons highlight arms race on the Korean peninsula
-
'Our future is being robbed': Greta Thunberg joins France student protests
-
Fiji appoint ex-Springboks boss White as coach ahead of World Cup
Medical Care Technologies Inc. (OTCID:MDCE) Reports First-Pass Results From Volunteer Image Evaluation Inside Melanoma Scan Beta
Initial Review Shows Real-World User Photos Can Move Through Quality Scoring, Body-Map Registration and Change-Over-Time Comparison
MESA, AZ / ACCESS Newswire / September 29, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today reported first-pass results from internal evaluation of its initial volunteer-submitted image datasets for MDCE Melanoma Scan Beta.

The update follows the September 16 announcement that the first human volunteer datasets had been received and the September 23 announcement that internal review had begun. Those releases established collection and the start of analysis. This release reports what the first evaluation pass showed.
Until the volunteer phase, development relied on public dermatology archives, including HAM10000, ISIC Archive collections, and TCIA melanoma cohorts. The first volunteer set introduced uncontrolled capture conditions. First-pass review was designed to answer a practical question: can those real-world photographs move through the beta workflow?
First-pass findings
Image-quality scoring
A substantial portion of the initial volunteer images met internal usability thresholds for focus, framing, and visible-area isolation. Images that did not meet those thresholds were held out of mapping and comparison. That split is itself a result: the workflow can separate usable samples from captures that are too distant, poorly lit, or too compressed for a comparison pass.
Body-map registration
Usable images were successfully assigned to mapped body regions inside the beta architecture. First-pass review indicated that volunteer photographs can be placed on the interactive body map with enough locational consistency to support later retrieval of the same site.
Longitudinal comparison
Where more than one usable image could be associated with the same mapped area, the platform completed side-by-side visual review. First-pass testing confirmed that successive user-captured images can be organized for change-over-time comparison. This finding concerns workflow function. It is not a medical result.
These first-pass outcomes do not constitute clinical validation, performance benchmarks, or diagnostic accuracy claims. They indicate that volunteer-submitted photographs can enter the system, be quality-filtered, be mapped, and - when a second image exists - be compared.
MDCE Melanoma Scan Beta is being developed as an AI-assisted imaging and body-map monitoring application intended to help users catalog visible skin images and review the same mapped area across sessions. The platform remains in beta-stage development. It has not received regulatory clearance and is not intended to diagnose, treat, cure, or prevent any disease or medical condition. It is not a substitute for professional medical advice, screening, or evaluation by a qualified healthcare provider.
"The first pass did what we needed it to do," said Marshall Perkins, CEO of Medical Care Technologies. "Real-world photos made it through quality scoring. They registered to the body map. Where we had more than one image of the same site, comparison ran. That is forward progress from collecting data to seeing the workflow function on volunteer input."
Volunteer participation is not a clinical diagnosis program. Any concern about a skin change should be reviewed by a licensed clinician. Medical Care Technologies will continue its multi-phase testing protocol and additional evaluation passes as more volunteer-submitted images are collected.
Investors and interested parties can learn more at:
https://www.medicalcaretechnologies.com
About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTCID: MDCE) is a diversified technology company focused on the development and commercialization of artificial intelligence-powered applications spanning health, wellness, nutrition, lifestyle, and enterprise imaging analysis solutions. Visit: https://www.medicalcaretechnologies.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and assumptions, and actual results may differ materially due to various risks and uncertainties. The company undertakes no obligation to update these statements except as required by law. Investors are cautioned not to place undue reliance on forward-looking statements.
Contact Information:
Medical Care Technologies Inc.
1910 S. Stapley Drive, Suite 221, Mesa, AZ 85204
Phone: +1 (480) 645-0750
Email: [email protected]
Website: https://www.medicalcaretechnologies.com
SOURCE: Medical Care Technologies Inc.
View the original press release on ACCESS Newswire
S.Gregor--AMWN